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Summary 
 
Lung cancer is the number one cause of cancer-related 
death involving excessive cell growth in epithelial 
tissues lining the lungs. Non-small cell lung cancer 
(NSCLC) is the most prevalent form of lung cancer. 
Genome-wide association studies provide insight into 
NSCLC. Single nucleotide polymorphism variations on 
chromosomes 15q24 and 15q25 lead to increased risk of 
NSCLC. Also, two tyrosine kinase receptors, epidermal 
growth factor receptor (EGFR) and human epidermal 
growth factor receptor 2 (HER2 / ERBB2), have mutated 
kinase domains associated with NSCLC. Proteins with 
Src homology 2 (SH2) and phosphotyrosine domains 
interact with EGFR and ERBB2, allowing proteins to 
bind to phosphotyrosine residues. Two of these 
proteins containing phosphotyrosine residues are 
vascular endothelial growth factor-A (VEGF-A) and 
platelet-derived growth factor receptor- ß (PDGFR-ß). 
These are present in the PI3K/Akt pathway involving 
angiogenic proteins p85 and p110. There are several 
drugs that inhibit these signaling pathways. Gefitinib 
inhibits the phosphorylation of mutant EGFR and 
ERBB2 receptors. Multiple mutations on kinase domains 
of EGFR and ERBB2 lead to higher Gefitinib sensitivity. 
Imatinib decreases phosphorylation of PDGFR-ß and 
VEGF-A, reducing tumor cell proliferation and cisplatin 
activates a signal-transduction pathway causing 
apoptosis of tumor cells involving p53 and p73 signaling 
pathways. 
 
Introduction 
 
Non-small cell lung cancer (NSCLC) is a carcinoma, or a 
malignant cancer that arises from epithelial tissue (University 
of Maryland, 2008). NSCLC is a disease involving 
uncontrolled cell growth in tissues lining the lungs, which 
could result in metastasis or the spread of disease into 
nearby tissue beyond the lungs (Chen et al., 2009). Because 
of its high rate of metastasis, NSCLC accounts for nearly 
80% of all lung cancers and is the leading cause of cancer-
related deaths worldwide (Jemal et al., 2008). Despite the 
lung cancer medical advances made, mortality rates are still 
high, with an overall five year survival of only 15% (Jemal et 
al., 2008).   
There are three major types of NSCLC: squamous 
cell carcinoma, which affects the skin, mouth, esophagus, 
and lungs, large cell carcinoma named after the large 
appearance of its cells under the microscope, and 
adenocarcinoma, which begins in cells lining the alveoli 
(University of Maryland, 2008). These different classes of 
NSCLC are named based on the types of cells they contain 
and how they look under a microscope. There are also minor 
forms of NSCLC, including pleomorphic, carcinoid tumor, 
and salivary gland carcinoma (University of Maryland, 2008). 
________________________________________________  
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Many risk factors are associated with NSCLC. 
Tobacco is the number one risk, accounting for nearly 90% 
of all incidences (Johnson et al., 2008). Each one year delay 
in starting to smoke a fixed daily cigarette decreases an 
individual’s lung cancer risk by 10% (Franks & Teich, 1986). 
However, there are other risk factors including exposure to 
radiation therapy, asbestos, radon, arsenic, and air pollution. 
Many times patients with NSCLC do not 
experience any symptoms. They are unaware that they have 
the disease until they undergo routine chest x-rays. If 
symptoms of lung cancer are present, they are caused by 
either a primary tumor or by metastatic cancer cells. A 
primary tumor is one which begins in the original organ and 
has not metastasized. Primary tumors usually damage 
surrounding tissues, blood vessels, or nerves (Alberg, Ford, 
& Samet, 2007). Metastatic lung cancer may cause the 
same problems, but in different areas of the body. The 
primary symptoms of non-small cell lung cancer include 
persistent coughing, wheezing, shortness of breath, chest 
pain, difficulty swallowing, hoarseness, loss of appetite, and 
recurrent respiratory infection (Johnson, 2009). These 
symptoms are very common, and it is important to get tested 
if any of them are persistent.   
There are several factors that affect the prognosis 
and treatment of non-small cell lung cancer. These include 
the size of the tumor, how far the cancer has metastasized, 
and the overall health of the patient (Schiller et al., 2002). 
There is currently no cure for NSCLC, and it is 
recommended for patients with all stages of NSCLC to take 
part in extensive clinical trials. Treatments for early-stage 
NSCLC include various types of surgery and radiation. 
Chemotherapy can be used to treat both early-stage and 
advanced NSCLC (Schiller et al., 2002). Treatment with 
Avastin and platinum-based chemotherapy involving 
cisplatin has been used since 2006 as a first-line treatment 
option for patients with advanced, non-squamous cancer 
(Hall et al., 2008).  
The molecular mechanisms involved in NSCLC 
are still relatively unknown and are being investigated 
extensively. Over the last decade, extensive research has 
been performed on tyrosine kinases, which are enzymes that 
can transfer a phosphate group from ATP to tyrosine 
residues, or amino acids, of proteins (Engelman et al., 
2007). Biological agents known as tyrosine kinase inhibitors, 
such as Gefitinib and Imatinib, are being studied as potential 
treatments of NSCLC (Engelman et al., 2007). These 
particular drugs block small, mutated protein kinase 
molecules involved in the growth of blood vessels that 
ultimately help promote tumor growth in the cell. These 
drugs have the potential to inhibit specific growth factors and 
their receptors, including EGFR, ERBB2, PDGFR-β, and 
VEGF-A. Researchers believe that by turning off these 
mutated protein molecules as well as the signaling pathways 
associated with them, inhibition of tumor cell proliferation will 
result. 
 
Implications of Chromosomal Loci in the Development 
of Lung Cancer 
 
Genome-Wide Association Studies and SNPs 
The recent completion of sequencing of the Human Genome 
has already begun to pay dividends in disease research. 
Through the use of genome-wide association studies, 
breakthroughs have been seen in the pathogeneses of many 
genetically complex diseases including diabetes, 
 
  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1. Properties of a healthy and mutated cell. This figure depicts the events that occur from the transcription and translation of EGFR and 
ERBB2 until the activation and signaling of the cell to proliferate.  A) Represents the absence of a mutation in EGFR and ERBB2, thus a regulated 
signal and healthy proliferation and division pursue.  B)  Depicts a point mutation in EGFR and ERBB2 and thus the upregulation of the proliferation 
signal and constant division leading to cancer. 
 
 
inflammatory bowel disease, heart disease, and cancer 
(Hung et al., 2008). Genome-wide association studies 
examine genetic variations amongst a particular genome, 
characterizing observed genotypic characteristics to 
observed phenotypes. Genome-wide association studies 
allow researchers to study large samples, which make these 
studies a key component to solving the mysteries of modern 
diseases. 
Recently, genome-wide association studies have 
provided great insight into the development of lung cancer. 
These studies have pinpointed specific loci on chromosomes 
that are strongly associated with risk of the disease. Single-
nucleotide polymorphisms (SNPs) are contained within these 
loci, which account for differences in a genome (Hung et al., 
2008). SNPs are single nucleotide variations in the DNA 
sequence that differ from that of the majority of the 
population. It is in these SNPs that variations occur which 
allow researchers to be able to associate specific SNPs and 
chromosomal loci to the development of lung cancer (Hung 
et al., 2008).  
 
Chromosomal Culprits 
Three known chromosomal culprits have already been 
identified as being highly associated with the development of 
lung cancer: 15q24, 15q25, and 5p15.33 (Chanock & 
Hunter, 2008). The 15q24 and 15q25 regions house many 
genes including nicotinic acetylcholine receptor subunits 
(Chanock & Hunter, 2008). Nicotinic acetylcholine receptor 
subunits stimulate acetylcholine-activated ion-channel-linked 
receptors in neurons when nicotine binds to them (Alberts et  
al., 2004). The genes found on the 5p15.33 region include 
the human telomerase reverse transcriptase (TERT) (McKay 
et al., 2008). Human telomerase reverse transcriptase is a 
protein subunit that catalyzes the enzyme telomerase, which  
 
 
 
is responsible for the addition of telomeres to the end of 
replicating DNA strands (Alberts et al., 2008). 
Genome-wide association studies were utilized to 
identify various SNPs associated with the risk of lung cancer 
on these loci. The SNP rs8034191 on region 15q25 was 
most prevalent amongst lung cancer cases, far exceeding 
the genome-wide significance level (Hung et al., 2008). On 
the 5p15.33 region, the SNP rs402710 was most frequently 
associated with increased risk of the disease. (McKay et al., 
2008). Interestingly, an SNP, rs1051730 was found on 
region 15q24 to not only be highly associated with risk of 
developing lung cancer, but also with high smoking quantity 
within lung cancer patients (Thorgeirsson et al., 2008). This 
link between smoking behavior and lung cancer provides a 
somewhat extraordinary gene-environment interaction. 
 
Gefitinib Interacts With EGFR/ERBB2 Pathway 
 
Receptor tyrosine kinases are proteins within cells that 
regulate various signaling pathways involved in critical 
cellular activities such as growth, motility, survival, and 
apoptosis (Pedersen et al., 2005).  One tyrosine kinase 
receptor important in cancer is known as epidermal growth 
factor receptor (EGFR).  Signaling of this membrane-bound 
receptor involves an intricate pathway of ligand binding, 
receptor homodimerization, and heterodimerization with 
ERBB2 and other family members, followed by 
internalization and recycling of the ligand-bound receptor or 
ubiquitin-mediated receptor degradation  (Fig. 1A) (Kwak et  
al., 2005). EGFR is frequently found overexpressed or 
mutated in many human malignancies including those of the 
brain, breast and lung (Pedersen et al., 2005). This 
overexpression stimulated the development of specific 
pharmacological tyrosine kinase inhibitors such as gefitinib.  
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Figure 2. New Biological Model: Pathways Leading to NSCLC and Treatment Options. A) Depicts the increased concentrations of ERBB2, EGFR, 
MET, PDGFR, and VEGF due to genetic mutations along with decreased affinity for the substrates, causes a proliferation signal to continuously be 
sent to the nucleus as seen.  B) Application of gefitinib, imatinib, and cisplatin results in the inhibition of tumor cell proliferation.  An MET inhibitor can 
also be used to inhibit cell proliferation.   
 
 
Gefitinib is an orally administered drug that disrupts EGFR 
kinase activity by binding to the ATP-binding pocket of the 
EGFR protein (Pedersen et al., 2005). This binding prevents 
the heterodimerization between EGFR and a family member 
of ErbB.  Heterodimerization is essential in order to start the 
cascade of signals that lead to cell growth, and in the cases 
with mutated EGFR, excessive cell proliferation.  
Independent studies have been conducted to 
determine the effects of gefitinib on patients with NSCLC.  It 
was found that gefitinib could suppress the tyrosine 
phosphorylations of cells expressing EGFR mutants 
(EGFRvIII) more effectively than the wild-type EGFR (Chen 
et al., 2006).  Interestingly, the concentration of gefitinib 
affects its inhibition capabilities. Research has shown that 
long term exposure to high concentrations of gefitinib (1-2 
µm) is needed to stop phosphorylation and signaling of PLC-
y and AKT by EGFRvIII cells when compared to wt-EGFR 
(Pedersen et al., 2005).  However, when low concentrations 
of gefitinib (0.01-0.1µm) were introduced, it appeared that 
the drug actually stimulated receptor autophosphorylation, 
proliferation and anchorage-independent growth of the 
EGFRvIII cells (Pedersen et al., 2005).  While this finding 
was consistent in all mutated EGFR cells, higher doses of 
gefitinib equated to a greater inhibition rate of EFGRvIII 
cells; it also showed a surprising result that researches could 
not quite explain.  Higher doses of gefitinib worked, but its 
ability to inhibit growth varied depending on the type of 
EFGR mutation. 
 
EGFR Mutations Do Not Have to be Located in the 
Kinase Domain to be Sensitive to Gefitinib  
 
Mutations in the kinase domain of EGFR are associated with 
clinical responsiveness to gefitinib in patients with NSCLC 
(Chen et al., 2006).  The most common oncogenic mutations 
found in patients with non-small cell lung cancer are small, 
in-frame deletions on exon 19 and the point mutation L858R 
(Yun et al., 2007). After many experiments, researchers 
found that gefitinib could suppress the tyrosine 
phosphorylation of most EGFR mutants better than the wild-
type receptor (Chen et al., 2006).  However, this research 
also found that gefitinib has variable growth-suppressive 
effects on different EGFR mutant-expressing cells (Chen et 
al., 2006).  It has been suggested that the increased binding 
affinity between mutant receptors and the inhibitor was the 
major cause of hypersensitivity to gefitinib (Chen et al., 
2006). However, this claim is no longer considered valid.  In 
2006, researchers used mutations that were located at 
distinct positions in the EGFR kinase domain and found that 
all of the mutations had a higher sensitivity to gefitinib (Chen 
et al., 2006).    Even more interesting, researchers found that 
the EGFRvIII mutant lacking a mutation in the kinase domain 
was more sensitive to gefitinib than the wild type EGFR 
(Chen et al., 2006).  These two pieces of evidence propose 
that a mutation in EGFR kinase domain is not essential for 
obtaining hypersensitivity to gefitinib and further suggests 
that hypersensitivity to gefitinib in mutated EGFR could 
possibly be derived from other properties that are introduced 
by the mutations (Chen et al., 2006). 
 
Classes of Proteins That Are Associated in Lung Cancer 
 
Phosphorylation of many membrane- bound proteins can 
lead to the activation of these proteins’ kinase function which 
sends a signal through consequent proteins by 
phosphorylation. Three amino acids have the ability to be 
phosphorylated: serine, threonine, and tyrosine. Specifically, 
these proteins are phosporylated at a tyrosine residue 
(amino acid). The signal can then be sent through receptor 
protein/kinases such as PI3K/p85, Akt, or STAT 5. (Rikova 
et al., 207). These proteins contribute to the rest of the 
pathway and must be phosphorylated to continue the signal.  
Specific domains, such as the Src homology 2 and 
phophotyrosine binding domain, bind to the phosphorylated 
tyrosine residue (Jones et al., 2006).  Once these proteins 
are activated, then the different signals, such as apoptosis, 
proliferation, and cell division, are sent to the nucleus to be 
activated (Jones et al., 2006).   
 
EGFR and ERBB2 contributions  
The EGFR (ERBB1) signaling pathway is one of the most 
known and well studied epidermal growth factor pathways 
that contribute to the development of lung cancer (Jones et 
al., 2006).  Some of the cell processes that are signaled 69	  
  	  
include apoptosis, cell cycle progression, and some even in 
adhesion signaling (Shilo & Yarden, 2007). Like EGFR, 
mutations in ERBB2 have been well studied. Typically, 
mutations in these genes cause an increase in concentration 
of ERBB2 and EGFR (Figure 1B). Consequently, the 
proliferation signal of the cell is continuously activated 
because when the concentrations of these proteins increase, 
their affinity thresholds for ligands decrease (Jones et al., 
2006). EGFR protein mutations represent 10% of all 
NSCLCs while ERBB3 protein mutations account for about 
5% (Rikova et al., 2007). This may seem minor, but it is 
important when other proteins such as PI3KA and B-RAF 
only account for 5% together (Rikova et al., 2007). Thus, the 
15% of NSCLC caused by EGFR and ERBB2 protein 
mutations are significant.  
 
Promiscuous Proteins 
Although EGFR and ERBB2, together, contribute to about 
15% of NSCLC, there are many more membrane bound 
proteins that contribute to mutations. However, before 2005, 
many of these proteins were not studied or even known 
about contributing to cancer (Rikova et al., 2007). Like 
EGFR, these proteins are kinases that can be activated by 
binding with the correct ligand and can then send the 
specific signal down the pathway using the Src domain and 
PTB domain as well (Jones et al., 2006). Over 20 different 
amplified proteins were found in one or more of the 11 cell 
lines and 12 tumor samples (Rikova et al., 2007).  
Specifically, of the 20 amplified proteins, MET, PDGFRa, 
ALK, and VEGF were most abundant (Figure 2A) (Rikova et 
al., 2007). These four proteins were found in more than five 
cell lines and 10 tumor samples each.  Over 22 different cell 
lines and 96 tumor samples from NSCLC patients, each 
containing more than 50% cancerous cells, were analyzed 
(Rikova et al., 2007). This is significant because these 
proteins are all normally found in healthy cells; however, 
amplification of these proteins and continuous signaling is a 
characteristic of cancer. Interestingly, the various proteins 
were not amplified in the same samples.   
The expression of these proteins may be cause by 
the abundance of EGFR and ERBB3 in cancerous cells. As 
their concentrations increase, they begin to bind more 
frequently and send their specific signal continuously 
through the cell (Jones et al., 2007). The ability for a cell to 
increase expression of different proteins and continuously 
activate many different pathways leads to decreased 
sensitivity toward treatments. Drugs such as gefitinib, an 
EGFR inhibitor, as well as MET inhibitors, will no longer be 
able to be used as independent treatments.  Instead, a 
cocktail of gefitinib and MET inhibitors might be necessary. 
When EGFR is inhibited by gefitinib, MET may become 
amplified due to a secondary mutation and, therefore, 
inhibition of MET is required. Both drugs would then be 
necessary as treatments to stop the signaling pathways of 
MET and EGFR (Engelman et al., 2007).  Depending on the 
type of NSCLC, more drugs, such as lamitinib-a PDGFR 
receptor inhibitor, may be used as well (Figure 2B) (Rikova 
et al., 2007). This drug would stop the phosphorylation of the 
membrane-bound kinases, thus halting the continuous signal 
to proliferate through the cell. 
  
Signal Transduction Mechanisms  
 
The PI3K/Akt Pathway 
The PI3K/Akt signaling pathway is linked to the growth, 
survival, migration, and invasion of malignant cancer cells. 
Evidence points to the importance of deregulated PI3K/Akt 
signaling in lung cancer (Chen et al., 2009). The activation of 
growth factor receptor protein kinases results in 
autophosphorylation on tyrosine residues and  
transphosphorylation of adaptor proteins on tyrosine 
(Ruddon, 2007). Phosphoinositide 3-kinase (PI3K) is brought 
to the membrane and activated by binding to 
phosphotyrosine residues of growth factor receptors or 
adaptors (Figure 2A) (Ruddon, 2007). The lipid product of 
PI3K, phosphatidylinositol-3,4,5-triphosphate (PIP3), obtains 
a subset of signaling proteins to the membrane where they 
become activated (Ruddon, 2007).  
One of these proteins is protein kinase B, or 
serine-threonine kinase Akt. Serine-threonine kinase Akt is 
the key downstream effector of PI3K, and it phosphorylates 
and regulates the activity of a number of targets in response 
to the activation of PI3K (Chen et al., 2009). Serine-
threonine kinase Akt and a number of other proteins initiate 
the complex set of events that control protein synthesis, cell 
cycle entry, cell survival, and actin polymerization. A very 
important regulatory step in the Akt pathway is the 
dephosphorylation of PIP3 to PIP2 by the protein 
phosphatase and tensin homolog, or PTEN, which is 
encoded by the PTEN gene (Ruddon, 2007). Overall, 
inhibition of PI3K/Akt activation and disruption of the 
associated proteins are implicated as promising approaches 
for lung cancer treatment (Chen et al., 2009). Feline Models 
of HCM: MYBPC3 Mutations 
In 2005, a research team lead by Dr. Kathryn 
Meurs discovered the first spontaneously occurring mutation 
causing heritable HCM in a non-human species.  The 
mutation was found in a family of Maine Coon cats that had 
been previously diagnosed with the disease.  HCM in this 
colony of cats was shown to closely resemble the human 
form by Kittleson et al. in 1999.  They found that, consistent 
with HCM in humans, these cats presented varying 
phenotypes, from mild to severe (Kittleson et al., 1999).  
These results lead to the proposal that affected cats are a 
valuable, naturally occurring animal model for studying the 
cellular, molecular, and anatomical aspects of HCM and may 
be an important resource for studying possible therapeutic 
treatments of the condition (Kittleson et al., 1999).  
In the study by Meurs et al. (2005), affected Maine 
Coon cats were determined to have a causative mutation in 
exon 3 of the feline ortholog of the MYBPC3 gene.  The 
mutation, a single base pair change of G to C, modified the 
amino acid sequence of the cMyBP-C protein, which was 
predicted to result in an alteration in protein structure.  This 
abnormal conformation may explain the sarcomeric 
disorganization and increased left ventricular wall thickness 
(range = 6-9 mm, normal = 3-5mm) observed in these cats.  
Furthermore, affected cats were found to have decreased 
levels of the cMyBP-C protein in their myocardium in 
comparison to control cats (p < 0.001).  This may indicate 
that the mutated proteins are degraded due to their instability 
and their inability to integrate into the sarcomere, supporting 
the previously mentioned findings by Sarikas et al. (2005).   
More recently, a second mutation in the feline 
MYBPC3 gene was identified in a similar population of 
Ragdoll cats with HCM (Meurs et al., 2007).  The mutation 
caused similar phenotypes, but was in a different domain 
than the Maine Coon mutation.  This suggests that the two 
mutations were independent and not the result of a common 
founder.  The mutations resulted in a change from arginine 
to tryptophan in the protein’s amino acid sequence due to a 
single base pair change from C to T in codon 820, yielding 
an abnormal protein product.  These discoveries in feline 
models of HCM provided more evidence for the importance 
of the MYBPC3 gene in cardiac structure and function and 
illustrate that it is a key component of hypertrophic 
cardiomyopathy in cats as well as humans. 
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Tyrosine Kinase Pathways and Protein Phosphatases 
Tyrosine kinase proteins are a large group of signal 
transduction proteins that include cell surface receptors for 
growth factors such as EGFR, ERBB2, PDGFR, and VEGFR 
(Moyer et al., 1997). There are a large number of 
cytoplasmic tyrosine kinases that activate downstream 
effectors and control a number of developmental, cell 
proliferation, and cell differentiation pathways (Ruddon, 
2007). The p85-α and p110-α subunits activate enzymes 
producing secondary messengers. Mutations usually lead to 
altered tyrosine kinase pathways and are observed in the 
PI3K signaling pathway. These changes ultimately decide 
whether activation or induction of nuclear transcription 
factors, to turn genes on or off, occurs. Phosphatase 
proteins play a major role in the activity of various receptors 
and particular cell cycle-regulating genes. Protein tyrosine 
phosphatases (PTPases) are a very unique group of 
enzymes present in the cell membrane, and typically 
associate with tyrosine kinase receptors (Ruddon, 2007). 
Evidence has shown that PTPases are involved in NSCLC. 
One in particular, PTEN, is considered to be a tumor 
suppressor because previous studies have shown that loss 
of PTEN activity increases PIP3 phosphorylation by PI3K 
(Chen et al., 2009). 
 
Angiogenesis 
 
Vascular Endothelial Growth Factor 
Angiogenesis is a normal process in which new blood 
vessels are formed for the development of many cells. This 
process is highly regulated, being turned on for specific 
periods of time and then shut off. However, in the case of 
tumor angiogenesis, the response is unregulated and results 
in many diseases. Angiogenesis is an important step in 
tumor cell proliferation because it creates an independent 
blood supply for the cancer cell (Helotera & Alitalo, 2007). It 
was not known until recently that endothelial cells produce 
VEGF, which is essential for angiogenesis to occur in cells. 
VEGF was originally thought to be only a tumor vascular 
permeability factor, but it is a major mediator of angiogenesis 
as well (Chen et al., 2009). Important to angiogenesis is 
autocrine VEGF, which follows a signaling pathway whereby 
a cell secretes a hormone or chemical messenger that binds 
to receptors on the same cell, causing intracellular changes 
(Alberts et al., 2004).  
VEGF is necessary for pathological growth of 
vessels in many diseases including NSCLC and 
investigations have been targeted to suppress VEGF 
signaling (Helotera & Alitalo, 2007). VEGF acts through both 
tyrosine kinase receptors VEGFR-1 and VEGFR-2, with 
VEGFR-2 being the major mediator of angiogenesis (Ferrara 
& Kerbel, 2005). Angiogenesis is required for metastasis of 
tumor cells, which must have increased expression of 
various metastasis-promoting genes. VEGF-A expression, a 
potent angiogenesis promoter, is observed in almost all 
aggressive tumors. VEGF-A also stimulates observed cell 
migration and invasion of cancers cells throughout various 
organs of the body by activating the PI3K/Akt pathway (Chen 
et al., 2009).  
 
FLJ10540 Protein 
FLJ10540 is a protein that may function as an oncogene in 
the development of tumors, and it has been shown in a 
recent study that it is required for necessary VEGF-A-
dependent signaling in the PI3K pathway. High levels of 
FLJ10540 help induce AKT phosphorylation and form a 
complex with PI3K (Chen et al., 2009). A recent experiment 
suggests that FLJ10540 is overexpressed in lung cancer 
tissues, and this is in positive correlation with the 
overexpression of VEGF-A, which leads to hyperactivation of 
the PI3K/Akt pathway (Chen et al., 2009). The 
overexpression of FLJ10540 thus contributes to cell changes 
and tumor cell proliferation through the activation of this 
pathway. In addition, FLJ10540 serves a critical role in 
enhancing cell migration and invasion, resulting in enhanced 
metastatic potential of cancer cells. There is an elevated 
upregulation of FLJ10540 in tumor lung tissue, indicating 
that there are both migratory and invasive qualities of lung 
cancer cells (Chen et al., 2009).   
 
Platelet-Derived Growth Factor 
Angiogenesis relies on more than solely VEGF-A to function. 
Platelet-derived growth factor (PDGF) has angiogenic effects 
in vitro and in vivo. Specifically, PDGF-β acts on pericytes 
covering blood vessels, which then secretes Ang1 to 
stabilize the formation of blood vessels (Helotera & Alitalo, 
2007). Angiopoietin-1 (Ang-1) is a protein that has an 
important role in blood vessel maturation and stability. This 
contributes to vascular development and angiogenesis as a 
whole. 
 
Current Drug Treatments for NSCLC: Tyrosine Kinase 
Inhibitors 
 
Imatinib is a specific PDGFR-ß inhibitor that inhibits the 
function of phosphorylated PDGFR- ß (p-PDGFR-ß), a 
tyrosine kinase receptor. It also decreases interstitial fluid 
pressure in cells, downregulates VEGF, and improves tumor 
oxygenation, which was shown in recent studies to be 
beneficial (Figure 2B). A major challenge related to drug 
delivery in tumor cells is related to the heterogeneous blood 
supply. In angiogenesis, excessive growth of blood vessels 
in tumors leads to extensive tumor interstitial fluid pressure 
(TIFP), which is marked by a reduced delivery of anticancer 
drugs (Vlahovic et al., 2006). High levels of IFP indicate 
solid, or malignant, tumors. Phosphorylated PDGFR-ß is a 
target for lower TIFP in tumors that overexpress PDGFR-ß. 
Imatinib treatment is shown to reduce IFP within tumors 
(Vlahovic et al., 2006). There is also improved tumor 
oxygenation with the use of Imatinib. Tumor hypoxia limits 
the curability of tumors because it involves depriving tumor 
cells of oxygen necessary for cytotoxic effects of radiation 
and chemotherapy. One cause of this is the inability of 
antitumor agents to penetrate beyond more than 50-100 µm 
from capillaries (Vlahovic et al., 2006). Another reason is 
that hypoxic tumor cells divide very slowly, and 
chemotherapy and radiation target rapidly-dividing cells 
(Vlahovic et al., 2006). Finally, the downregulation of VEGF 
is present in Imatinib treatment, thus inhibiting the process of 
angiogenesis. 
 
Anti-Cancer Drug: Cisplatin 
Although there is no known cure for NSCLC, clinical trials 
have led to a variety of treatment options including platinum 
(Pt) based drugs. Effectiveness of the Pt drug is related to its 
accumulation within a cell. Resistance to current anticancer 
treatments has been linked to poor cellular absorption of the 
drug. The amount of Pt based drug entering cells is 
increased compared to these other drugs. Pt based drugs 
cross the cell membrane via either passive diffusion or active 
uptake by transport proteins (Hall et al., 2008). Once inside 
the nucleus, the Pt-containing drug functions by creating 
crosslinks within DNA (Poklar et al., 1996). A cis-Pt-GG 
intrastrand crosslink is formed when two adjacent N-7 
guanine bases coordinate with the platinum (Ohndof et al., 
1999). As a result of the crosslink, the Pt-DNA adduct 
unwinds and bends the DNA. Therefore, the two DNA 
strands cannot properly separate and the processes of 
replication and transcription become impaired (Hall et al., 
2008).  71	  
  	  
One such Pt anticancer drug is cis-
diamminedichloridoplatinum(II), also known as cisplatin 
(CDDP). After CDDP has modified the DNA of a cell, the Pt-
DNA adduct activates a signal-transduction pathway which 
leads to apoptosis. Two distinct pathways act in CDDP 
induced cell death: a p53 and a p73 pathway. P53 is a tumor 
suppressor; similarly, p73 is a homologue of p53. The p53 
pathway can be induced by CDDP as well as a variety of 
DNA-damaging agents such as ultraviolet radiation (Figure 
2B) (Gong et al., 1999). The p73 pathway is induced by 
CDDP via the nuclear enzyme non-receptor tyrosine kinase 
c-Abl (White & Prives, 1999). In order for c-Abl to induce 
p73, it must first become activated by a DNA damaging 
agent, such as CDDP (Yuan et al., 1999).  
Expression of c-Abl led to an increase in the 
amount of p73 but not p53, indicating that the presence of c-
Abl is required for p73 to function optimally. Further evidence 
for this was the co-expression of c-Abl and p73 but not p53 
(Gong et al., 1999). C-Abl is activated when it is 
phosphorylated by a protein kinase known as 
ataxiatelangiectasia-mutated (White & Prives, 1999). The 
absence of c-Abl disrupts the G1-S checkpoint in response 
to DNA damage while the activation of c-Abl allows p73 to 
accumulate within the cell and induce apoptosis (Gong et al., 
1999).  
In order for p73 to initiate cell cycle arrest, the Pt 
damaged cell must interact with a high mobility group 
domain (HMG). HMG-domain proteins, including p73, are 
attracted to the Pt-DNA adduct and bind to the DNA at a 
phenylalanine residue on the crosslinked site of the Pt-DNA 
adduct. Mutant cells, in which alanine is substituted for 
phenylalanine, have reduced binding of the HMG- domain to 
the DNA and, therefore, display reduced sensitivity to CDDP 
(Ohndorf et al., 1999). Studying these interactions is 
necessary to design new anticancer drugs with increased 
affinity for Pt-modified DNA. 
 
Conclusion 
 
Non-small cell lung cancer is a carcinoma arising from 
epithelial tissues and is characterized by uncontrolled cell 
growth in the tissues lining the lungs. Specific loci that 
contain single-nucleotide polymorphisms (SNPs) cause 
differences in the human genome that lead to the 
development of lung cancer. SNPs located at chromosomes 
15q24, 15q25, and 5p15.33 are associated with the 
development of lung cancer. The SNP on region 15q25 is 
the most prevalent in lung cancer. Tyrosine kinase receptors 
are proteins that regulate signaling pathways involved in 
growth, motility, survival, and apoptosis of cells. Epidermal 
growth factor receptor is overexpressed or mutated in lung 
cancer along with ERBB2 in a heterodimerization essential 
to start the cascade of cell proliferation signals. Not only is 
EGFR and ERBB2 overexpressed in NSCLC, but in over 20 
different membrane bound proteins including MET, PDGFR, 
and VEGF.  VEGF is important because it induces the PI3K 
pathway to stimulate angiogenesis, which allows the tumor 
to grow.  Treatments can block the ability for EGFR to 
become self-phosphorylated, as the case with gefitinib, or 
function as PDGFR and VEGF inhibitors (Imatinib).  Another 
type of drug, cisplatin, can induce p53 and p73 to cause the 
cell to apoptose.  Thus, there are many different kinds of 
mutations that can occur in NSCLC.  Some can occur from 
smoking, such as EGFR and ALK mutations. However, 
some mutations can occur spontaneously such as the ROS, 
MET, and PDGFR mutations (Rikova et al. 2007).  This 
means that current treatments may have to be used in a 
cocktail to account for all the different possible protein 
mutations. To further study the use of the cocktail of drugs, 
trials must be moved from in vitro to in vivo within animal 
models. Consequently, mutations can occur even after one 
tyrosine kinase is inhibited.  Thus, new research must be 
done to discover further secondary mutations.  The next step 
is to further study associations between amplified proteins in 
resistant NSCLC cell lines and tumor samples. Further 
research needs to be conducted into the process of 
metastasis with regards to NSCLC. Finally, we need to take 
a deeper look at other drugs that may lead to a destruction 
of the tumor cells themselves. For example, as mentioned 
before, Cisplatin is a platinum-based drug that kills the 
cancer cell. Although very toxic, these drugs need to be 
researched further because they by-pass further secondary 
mutations and are able to destroy the cancerous cells.  
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